Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Odiparcil

Small molecule · developed by Inventiva Pharma

Phase 2 Most advanced trial (none active)
IVA Developer
1 Registered trials

What is Odiparcil?

Odiparcil is an oral tablet investigated in mucopolysaccharidosis VI.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Metabolic
Developer
Inventiva Pharma (IVA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FIK1414ZI8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03370653 Phase 2 Mucopolysaccharidosis VI Completed IVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mucopolysaccharidosis VI

More from Inventiva Pharma

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IVA page.

Follow IVA, the company behind Odiparcil

See IVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IVA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.